AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02650310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermostable device
Description: Investigators place the catheter with the loaded embryos into a plastic device at 37ºC in order to maintain the temperature
Study NCT04453150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard hypocaloric die
Description: Standard hypocaloric diet
Study NCT04453150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent fasting 16/8 (early fasting)
Description: Intermittent fasting 16/8 (early fasting)
Study NCT05392660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assumed upright position during first stage of labor
Description: The study group assumed one of upright positions during first stage of labor, defined as walking , sitting, standing, kneeling \& squatting positions )
Study NCT02960906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: For Arms 1A and 4A:~Nivolumab alone administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~For Arms 1B, 2B, 3B and 4B:~Nivolumab administered IV over 60 minutes at 3 mg/kg combined with ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks for 4 doses followed by nivolumab administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference.
Study NCT02960906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: For Arms 1B, 2B, 3B and 4B:~Ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks combined with Nivolumab administered IV over 60 minutes at 3 mg/kg for 4 doses until disease progression, unacceptable toxicity or other reasons specified in the protocol.
Study NCT02960906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: For Arms 2C and 3C (TKI pazopanib or sunitinib):~Pazopanib 800 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol
Study NCT04453150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent fasting 16/8 (late fasting)
Description: Intermittent fasting 16/8 (late fasting)
Study NCT02960906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: For Arms 2C and 3C (TKI pazopanib or sunitinib):~Sunitinib 50 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol
Study NCT02612675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ONS
Study NCT02612675 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ONS
Study NCT01719276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Graded Activity
Description: The graded activity program to increase activity tolerance by performing individualized and submaximal exercises.
Study NCT01719276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercises
Description: The group will perform stretching exercises (gluteus maximus, hamstrings, triceps surae, lumbar paraspinal), strengthening muscles (rectus abdominus, obliques and lower rectus abdominis internal and external) and motor control exercises (muscle transversus abdominis and lumbar multifidus.
Study NCT03421561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stellarex 0.035 OTW Drug-coated Angioplasty Balloon
Description: The Stellarex 0.035 OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm.
Study NCT03421561 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: EverCross™ 0.035 PTA Balloon Catheter
Description: The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).
Study NCT00250718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine should be administered intravenously through a freely-running IV.
Study NCT00250718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: The VP-16 is optional for the first cycle if the patient has delays in obtaining the drug.
Study NCT00250718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: The total amount of rituximab needed for a patient's entire infusions (one course) will be determined at study entry. A single dose of 375 mg/m2 will be based upon the patient's actual body surface area calculated during the baseline evaluation. The dose level of rituximab will not be adjusted.~Patients will only receive rituximab if their tumors are CD20 positive CLL or NHL.~Rituximab will only be administered to patients if they have previously had less than 8 doses. If a patient is treated with rituxan they should have at least 4 doses
Study NCT00250718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered at 200mg q 14 days. Dexamethasone should be administered over a 1 hour infusion.
Study NCT00250718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin will be administered at 500 mg PO qd.
Study NCT03015701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: a 19 norsteroid with anti-progesterone and anti glucocorticoid activity which competitively inhibits binding of the hormone to its receptor
Study NCT03015701 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo matching mifepristone
Study NCT01377506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle counseling
Description: 21 session group-based behavioral weight management program delivered in senior center over 12 months by lay health educators
Study NCT01377506 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: 21 session group-based cognitive training program delivered in senior center over 12 months by lay health educators
Study NCT01132755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic peritoneal lavage
Description: The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon. Caudal traction will be applied to the abdominal wall to provide a firm abdominal wall to insert the needle through, minimizing the peritoneum from tenting down closer to visceral structures. Intraperitoneal placement of the catheter will be confirmed by injection of saline into the needle with no resistance and with the saline in the hub of the needle falling into the peritoneal cavity spontaneously. A guide wire will be placed through the Veress and utilizing the Seldinger technique, a 9Fr peritoneal catheter will be placed.
Study NCT00444249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: White Alcon IOL
Description: Implantation of white Alcon IOL
Study NCT00444249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Alcon IOL
Description: Implantation of yellow Alcon IOL
Study NCT00444249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: White Hoya IOL
Description: Implantation of white Hoya IOL
Study NCT00444249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Hoya IOL
Description: Implantation of yellow Hoya IOL
Study NCT02769520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
Study NCT00762177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush twice a day for 14 days
Study NCT00762177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride, Triclosan
Description: Brush twice daily for 14 days
Study NCT00762177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride
Description: Brush twice daily for 14 days
Study NCT01486394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused Sonography of the heart, lungs and deep veins
Description: The patient is randomised to either a control group where usual treatment and diagnostic work-up is performed or to an intervention group where usual treatment and diagnostic workup are supplemented by a sonographic examination of the heart, lungs and deep veins are performed within one hour after the primary evaluation. The primary evaluation is defined as the first evaluation of the patient by a physician in the Acute Medical Admission Department.
Study NCT03826004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine
Description: Clemastine fumarate 2mg/2ml intramuscular injection is administrated into the gluteus maximus muscle
Study NCT03826004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Saline solution 2ml intramuscular injection is administrated into the gluteus maximus muscle
Study NCT00731003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxitriptan
Description: 100 mg 5-Hydroxytryptophan will be administered orally.
Study NCT00731003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Description: Acute tryptophan depletion employs the oral ingestion of an amino acid mixture devoid of tryptophan, the precursor of serotonin, which results in lowered serotonin levels.
Study NCT00731003 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Amino acid drink with tryptophan
Description: Amino acid drink with tryptophan, placebo for the ATD procedure
Study NCT00731003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo for 5-HTP
Study NCT01457430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: 30 mg subcutaneous dose of Icatibant
Study NCT00401115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-R001 (rapamycin)
Description: Subconjunctival injection in various dosages
Study NCT00401115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-R001 (rapamycin)
Description: Intraocular injection in various dosages
Study NCT00936338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: splint and joint mobilization self exercise
Study NCT00206960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zuclopenthixol
Description: Patients will be administered zuclopenthixol orally in doses between 4 -24 mg/day, depending on an effective reduction of symptoms
Study NCT03853837 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: rest-exercise echocardiography
Description: an echocardiogram performed during rest and exercise
Study NCT04144764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workplace-based exercise
Description: Participants will have to perform 10-week of workplace-based exercise programme which consist of 5 sessions of 10 minutes per week. The workplace-based exercise programme will consist of general stretching and strengthening exercise using resistance tubing for both the neck and upper limb. Specific rotator cuff and scapular muscles strengthening exercise were also included to enhance glenohumeral and scapular kinematics (Appendix). Each participant will receive a set of elastic resistance tubing that comprise red (2kg), green (3kg) and blue (4kg). The exercise programme will be taught by physiotherapist during their baseline assessment. They will be asked to train at the workplace during workdays (Monday to Friday), five times a week during the 10-week intervention. The program built on the principle of progressive overload.
Study NCT04144764 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ergonomic advice and education
Description: Participants will receive ergonomic training and education on how to adjust their workstations to reduce the ergonomic risk factors when using computers.
Study NCT00890318 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ABT-072
Description: Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.
Study NCT00890318 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ketoconazole
Description: Tablet, see Arm Description for intervention information.
Study NCT00890318 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.
Study NCT02546141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: skimmed milk (UHT)
Study NCT02546141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: skimmed milk (pasteurized)
Study NCT02546141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: skimmed yoghurt
Study NCT02546141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: full-fat milk (UHT)
Study NCT02546141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-homogenized full-fat milk (pasteurized)
Study NCT02546141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: full-fat cheese (semi-matured)
Study NCT02546141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whey protein
Study NCT02546141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: micellar casein
Study NCT00907114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac tromethamine
Description: Presentation 5 mg/ml; Dosage: one drop (0.25 mg) four times a day during one week after panphotocoagulation
Study NCT00907114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polivynilic alcohol
Description: Presentation: alcohol polivinilico 14 mg/ml; Dosage: one drop (0.7 mg alcohol polivinilico) four times a day during one week after panphotocoagulation
Study NCT05252975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Setup and Imaging for at CT radiation planning
Description: Patients will undergo an additional CT scan acquisition at CT radiotherapy planning in order that all participating patients have a prone and supine CT scan available to compare radiation therapy plans.
Study NCT05252975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Setup and Imaging for at CT radiation planning
Description: Patients will undergo an additional CT scan acquisition at CT radiotherapy planning in order that all participating patients have a prone and supine CT scan available to compare radiation therapy plans.
Study NCT01106950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cells
Description: Given by infusion on Day 0. The product is T cell-depleted (CD3-) and B cell-depleted (CD19). Target dose for infusion is \< or = 8 x 10\^7 nucleated cells/kilogram.
Study NCT01106950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered as a 1 hour intravenous infusion once a day for 5 doses beginning on day -6.
Study NCT01106950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered as a 2 hour intravenous infusion with high volume fluid flush and mesna per institutional guidelines on day -5 and -4 one hour after fludarabine infusion. (Day -4 administration may be omitted if patient has had a transplant in the previous 4 months.)
Study NCT01106950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox
Description: 12 ug/kg/day will be administered on day -1 and day -2 intravenously.
Study NCT01106950 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor lymphapheresis
Description: Day -1 before planned NK cell infusion, the donor will undergo lymphapheresis (Removal of lymphocytes from donated blood, with the remainder of the blood retransfused into the donor).
Study NCT01106950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Administered after NK cell infusion, 10 million units every other day for a total of 6 doses. (Patients weighing less than 45 kilograms will receive a dose of 5 million units/m\^2 every other day for 6 doses).
Study NCT02825459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence from e-cigarettes
Description: Abrupt cessation for 6 days
Study NCT00558883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acarbose
Description: oral application
Study NCT00558883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acarbose
Description: oral application
Study NCT03105401 — intervention group
Intervention type: OTHER
Intervention: Assessment of hallucinations in Parkinson's disease
Description: Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.
Study NCT02468700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02468700 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Study NCT02082288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Edessy ICSI Outcome Embryo Score
Description: EIOS:~Age (ys) >35 (0) 30-35 (1) \<30 (2) No of retrived oocyte \<5 (0) 5-9 (1) ≥ 10 (2) No of EC embryos \<2 (0) 2-4 (1) >4 (2) No of good quality embryos \<3 (0) 3-5 (1) >5 (2) No of embryos transferred -------- (0) ≤2 (1) >2 (2)
Study NCT03967327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patches
Description: It should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest. The skin should be relatively hairless. If none are available, the hair at the site should be clipped, not shaven.
Study NCT03967327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine transdermal patches
Description: It should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest. The skin should be relatively hairless. If none are available, the hair at the site should be clipped, not shaven.
Study NCT03967327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate Sustained-Release Tablet
Description: It will be administered orally twice (q12h) daily.
Study NCT03967327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate Sustained-Release Tablet
Description: It will be administered orally twice (q12h) daily.
Study NCT02123875 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy
Study NCT02123875 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control arm
Description: Routine hospital based physiotherapy
Study NCT01410253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of four techniques of physiotherapy
Description: The patients receive conventional physiotherapy, expiratory positive airway pressure, inspiratory muscle training and physical exercise. Twice daily for seven days
Study NCT01410253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of three techniques of physiotherapy
Description: Patients receive conventional physiotherapy, expiratory positive airway pressure and physical exercise. Twice daily for seven days
Study NCT01410253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of two techniques of physiotherapy
Description: Patients receive conventional physiotherapy,expiratory positive airway pressure respiratory muscle training. Twice daily for seven days
Study NCT01410253 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard therapy
Description: Patients receive conventional physiotherapy and expiratory positive airway pressure. Twice daily for seven days
Study NCT00669344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exelon (rivastigmine)
Description: Capsules, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
Study NCT00669344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
Study NCT05625464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCTP
Description: Real-time automated monitoring of the electronic medical record to identify suspected sepsis patients without completion of sepsis bundle measures within 1-hour of the completion deadline and generated reminder pages. Clinicians responsible for patients randomized to the intervention receive reminder pages whereas no pages are sent for control arm patients.
Study NCT00143572 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Magnesium Pidolate, Hydroxyurea
Description: Intervention Description: Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months. Mg pidolate will be given at an initial dose of 0.6 mEq/kg/day divided into 2 daily doses for the first cohort of patients. This dose will be escalated for the subsequent patient cohorts as defined by a classic Phase I design (according to toxicity).
Study NCT05562921 — intervention group
Intervention type: BEHAVIORAL
Intervention: Controls-ususal care
Description: Controls: patients who did not receive remote patient monitoring for blood pressure prescribed during routine care delivery, with multivariable matching to cases